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The rapid progression in the development of liver 
transplantation during the last decade is largely attributed 
by the standardization of operative techniques (1,2) and 
advances in the pharmacokinetics of immunosuppressive 
therapy (3). Such improvements in the perioperative 
management have rendered liver transplantation a safer 
operation and in turn translated into better long-term 
survival (4,5). As such, the indication for liver transplantation 
has been expanded to include malignant liver tumor other 
than liver cirrhosis. Since the proposal of Milan criteria by 
Professor Mazzaferro in the late 1990s, liver transplantation 
has been universally adopted as the curative treatment for 
early staged hepatocellular carcinoma (HCC) in patients 
with liver cirrhosis (6). As a result, the 5-year overall survival 
rate has reached up to 70% in various series (7,8). More 
importantly, the introduction of Milan criteria has since 
revolutionized the indications for transplantation and the 
allocation policy for cadaveric organs. 
As success was witnessed in the surgical management of 
HCC with transplantation, the indication has been extended 
to include other form of solid liver malignancies such as 
neuroendocrine liver metastasis and cholangiocarcinoma in 
the hope that similar survival outcome could be attained.
Neuroendocrine tumor is a highly vascular tumor 
with variable aggressiveness. It embraces a wide spectrum 
of tumor that arises from the neuroendocrine cells in 
the gastrointestinal tract and pancreas. For untreated 
neuroendocrine liver metastasis, the 5-year survival is 
approximately 30-40%. With transplantation, the survival 
for patients with unresectable neuroendocrine liver 
metastasis has drastically improved to 80% at 5 years in 
recent study (9). On the other hand, transplantation in 
patients with cholangiocarcinoma had a longer history 
of development that could be dated back to the early 
1990s. At that time, the outcome was rather disappointing 
with a 5-year survival rate of merely 5-10% (10). 
With the advancement of chemoradiation in recent years, 
the survival outcome has been drastically improved. 
Using the Mayo protocol i.e., neoadjuvant radiotherapy, 
chemosensitization with 5-FU and oral capecitabine 
for patients with early cholangiocarcinoma <3 cm and 
concomitant primary sclerosing cholangitis, both the 3- and 
5-year survival rates are reported to be approximately 80% 
respectively (11).
Despite the improved oncological outcome of liver 
transplantation to non-HCC liver tumor, the experience so 
far is limited to certain centers only. The lack of enthusiasm 
of transplant centers to embark on such a program is partly 
related to the scarcity of donor organ that prohibits a 
liberal allocation other than to those with end-stage liver 
diseases or early staged unresectable HCC. Second, the 
uncertain malignant potential of these tumors and the 
variable oncological outcomes after transplantation are 
major concerns for adoption of such treatment strategy. It 
is noteworthy to highlight that since this group of patients, 
by enlarge does not have liver failure or complications 
related to cirrhosis, the primary endpoint that defines 
the efficacy of transplantation in this setting should be 
the recurrence-free survival and overall survival. A high 
recurrence rate after transplantation could potentially pose 
another challenge to the clinicians. From our experience 
in HCC, recurrence after liver transplantation is often 
extrahepatic (12) and the lack of effective treatment options 
for extrahepatic recurrences is another important reason 
that limits the widespread application of transplantation to 
other types of liver malignancy. 
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As the incidence of colorectal cancer is on a rising trend 
in the developed world, it is conceivable to anticipate that 
the frequency of colorectal liver metastasis is bound to 
increase in the forthcoming era. Resection has been proven 
to be an efficacious treatment for colorectal liver metastasis 
with a 5-year survival rate of 40-50% (13,14). However, 
multiple bilobar liver metastases occur frequently that often 
preclude patients from potentially curative resection. In 
the May 2013 issue of Annals of Surgery, Hagness and co-
workers proposed the use of transplantation for unresectable 
colorectal liver metastasis and reported their preliminary 
experience in twenty-one patients (15). The 5-year overall 
survival rate was 60% and eight patients remained eligible 
for further treatment when recurrences were developed. 
Although the findings of this study seemed to be rather 
promising, one has to be cautious on further analyzing their 
results. First, there were no standardized selection criteria 
for recruitment of patients for this treatment. Second, the 
follow up duration was merely 27 months with less than 
50% of patients available for assessment at 3 years. More 
importantly, only 35% patients remained recurrence free 
at one year and no patient was recurrence free at two years. 
With regard to the post-transplant management, mTOR 
inhibitor was the preferred immunosuppressive agent for 
this cohort of patients. It remains questionable if mTOR 
inhibitor could inhibit the proliferation of metastatic 
cancer cells and in light of a 38% acute cellular rejection 
rate among their patients, the efficacy of adopting such 
immunosuppressive regimen is certainly subject to 
skepticism.
In my opinion, it is difficult to concur with the authors 
that liver transplantation is a feasible treatment for 
unresectable colorectal liver metastasis based on the survival 
figures that were provided by Hagness and co-workers (15). 
More clinical data needs to be accumulated by this 
center before we can truly ‘say’ this treatment strategy 
is feasible with oncological benefit. Until this time, liver 
transplantation for unresectable colorectal liver metastasis 
should not be undertaken as a routine procedure. 
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